{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:17:14Z","timestamp":1777879034968,"version":"3.51.4"},"reference-count":132,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T00:00:00Z","timestamp":1316995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Endocrinology"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:p>Therapeutic options for advanced, unresectable radioiodine-resistant thyroid cancers have historically been limited. Recent progress in understanding the pathogenesis of the various subtypes of thyroid cancer has led to increased interest in the development of targeted therapies, with potential strategies including angiogenesis inhibition, inhibition of aberrant intracellular signaling in the MAPK and PI3K\/AKT\/mTOR pathways, radioimmunotherapy, and redifferentiation agents. On the basis of a recent positive phase III clinical trial, the RET, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR) inhibitor vandetanib has received FDA approval as of April 2011 for use in the treatment of advanced medullary thyroid cancer. Several other recent phase II clinical trials in advanced thyroid cancer have demonstrated significant activity, and multiple other promising therapeutic strategies are in earlier phases of clinical development. The recent progress in targeted therapy is already revolutionizing management paradigms for advanced thyroid cancer, and will likely continue to dramatically expand treatment options in the coming years.<\/jats:p>","DOI":"10.1177\/2042018811419889","type":"journal-article","created":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T06:30:52Z","timestamp":1317018652000},"page":"173-195","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":44,"title":["Thyroid cancer: pathogenesis and targeted therapy"],"prefix":"10.1177","volume":"2","author":[{"given":"David A.","family":"Liebner","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha H.","family":"Shah","sequence":"additional","affiliation":[{"name":"A438 Starling-Loving Hall, 320 W 10th Ave, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2011,9,26]]},"reference":[{"key":"bibr1-2042018811419889","doi-asserted-by":"crossref","unstructured":"Ain, K.B., Lee, C., Holbrook, K., Dziba, J.M. and Williams, K.D. (2008) Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results.\n                      J Clin Oncol\n                      26(15S): abstract 6027.","DOI":"10.1200\/jco.2008.26.15_suppl.6027"},{"key":"bibr2-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.0289"},{"key":"bibr3-2042018811419889","doi-asserted-by":"crossref","unstructured":"Akerley, W., Schabel, M., Morrell, G., Horvath, E., Yu, M., Johnsson, B. et al. (2007) A randomized phase 2 trial of combretastatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies.\n                      J Clin Oncol\n                      25(18S): abstract14060.","DOI":"10.1200\/jco.2007.25.18_suppl.14060"},{"key":"bibr4-2042018811419889","unstructured":"Altekruse, S., Kosary, C., Krapcho, M., Neyman, N., Aminou, R., Waldron, W.\n                      et al.\n                      (2010) Seer Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. http:\/\/seercancergov\/csr\/1975_2007."},{"key":"bibr5-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.17"},{"key":"bibr6-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1184"},{"key":"bibr7-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0947"},{"key":"bibr8-2042018811419889","first-page":"192","volume":"33","author":"Bauer A.J.","year":"2003","journal-title":"Ann Clin Lab Sci"},{"key":"bibr9-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/105072502320908286"},{"key":"bibr10-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800198"},{"key":"bibr11-2042018811419889","doi-asserted-by":"crossref","unstructured":"Behlendorf, T., Voigt, W., Mueller, T., Jordan, K., Arnold, D. and Schmoll, H. (2009) Activity of mTor inhibitor Rad001 (everolimus) in differentiated and anaplastic thyroid cancer cell lines.\n                      J Clin Oncol\n                      27(15S): abstract e14608.","DOI":"10.1200\/jco.2009.27.15_suppl.e14608"},{"key":"bibr12-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70203-5"},{"key":"bibr13-2042018811419889","first-page":"P0189","author":"Braunstein G.","year":"2010","journal-title":"In: 14th International Thyroid Congress"},{"key":"bibr14-2042018811419889","doi-asserted-by":"publisher","DOI":"10.2741\/3696"},{"key":"bibr15-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205938"},{"key":"bibr16-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0417"},{"key":"bibr17-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj069"},{"key":"bibr18-2042018811419889","first-page":"7284","volume":"62","author":"Carlomagno F.","year":"2002","journal-title":"Cancer Res"},{"key":"bibr19-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0994"},{"key":"bibr20-2042018811419889","first-page":"189","volume":"19","author":"Chaplin D.J.","year":"1999","journal-title":"Anticancer Res"},{"key":"bibr21-2042018811419889","doi-asserted-by":"crossref","unstructured":"Cohen, E., Needles, B., Cullen, K., Wong, S., Wade, J., Ivy, S. et al. (2008a) Phase 2 study of sunitinib in refractory thyroid cancer.\n                      J Clin Oncol\n                      26(15S): abstract 6025.","DOI":"10.1200\/jco.2008.26.15_suppl.6025"},{"key":"bibr22-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9566"},{"key":"bibr23-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.8.625"},{"key":"bibr24-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0110"},{"key":"bibr25-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209267"},{"key":"bibr26-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.18.2164"},{"key":"bibr27-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0649"},{"key":"bibr28-2042018811419889","doi-asserted-by":"crossref","unstructured":"De Souza, J., Busaidy, N., Zimrin, A., Seiwert, T., Villaflor, V., Poluru, K.\n                      et al\n                      . (2010) Phase II trial of sunitinib in medullary thyroid cancer (MTC).\n                      J Clin Oncol\n                      28(15S): abstract 5504.","DOI":"10.1200\/jco.2010.28.15_suppl.5504"},{"key":"bibr29-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(98)00238-4"},{"key":"bibr30-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.3002"},{"key":"bibr31-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1177\/030089169007600513"},{"key":"bibr32-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2185::AID-CNCR18>3.0.CO;2-4"},{"key":"bibr33-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540190047028"},{"key":"bibr34-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-06-0695"},{"key":"bibr35-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00973"},{"key":"bibr36-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02089.x"},{"key":"bibr37-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01086"},{"key":"bibr38-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgm174"},{"key":"bibr39-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-1258"},{"key":"bibr40-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.130"},{"key":"bibr41-2042018811419889","doi-asserted-by":"crossref","unstructured":"Glen, H., Boss, D., Morrison, R., Roelvink, M., Wanders, J., Mazur, A.\n                      et al\n                      . (2008) A phase I study of E7080 in patients (Pts) with advanced malignancies.\n                      JClin Oncol\n                      26(15S): abstract 3526.","DOI":"10.1200\/jco.2008.26.15_suppl.3526"},{"key":"bibr42-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6692174"},{"key":"bibr43-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2762"},{"key":"bibr44-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3279"},{"key":"bibr45-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0057"},{"key":"bibr46-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0702"},{"key":"bibr47-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1899"},{"key":"bibr48-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0313"},{"key":"bibr49-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1125"},{"key":"bibr50-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0652"},{"key":"bibr51-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1"},{"key":"bibr52-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24272"},{"key":"bibr53-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20936"},{"key":"bibr54-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0371"},{"key":"bibr55-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02389.x"},{"key":"bibr56-2042018811419889","first-page":"1454","volume":"63","author":"Kimura E.T.","year":"2003","journal-title":"Cancer Res"},{"key":"bibr57-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1610041"},{"key":"bibr58-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0403"},{"key":"bibr59-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.2717"},{"key":"bibr60-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0047"},{"key":"bibr61-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1836"},{"key":"bibr62-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0193"},{"key":"bibr63-2042018811419889","doi-asserted-by":"crossref","unstructured":"Kurzrock, R., Cohen, E.E., Sherman, S., Pfister, D., Cohen, R.B., Ball, D.\n                      et al\n                      . (2010) Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of Xl184 (BMS 907351), an oral inhibitor of Met, VEGFR2, and Ret.\n                      J Clin Oncol\n                      28(15S): abstract 5502.","DOI":"10.1200\/jco.2010.28.15_suppl.5502"},{"key":"bibr64-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0068"},{"key":"bibr65-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2001.112592"},{"key":"bibr66-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1077"},{"key":"bibr67-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.5536"},{"key":"bibr68-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1999.9.421"},{"key":"bibr69-2042018811419889","doi-asserted-by":"publisher","DOI":"10.2174\/1568008043339802"},{"key":"bibr70-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0055"},{"key":"bibr71-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0776"},{"key":"bibr72-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910630525"},{"key":"bibr73-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2009.06.021"},{"key":"bibr74-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0321"},{"key":"bibr75-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(00)80015-1"},{"key":"bibr76-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605056"},{"key":"bibr77-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1921"},{"key":"bibr78-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700306"},{"key":"bibr79-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030305"},{"key":"bibr80-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1385\/EP:13:1:03"},{"key":"bibr81-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030838"},{"key":"bibr82-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602461"},{"key":"bibr83-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2010.05.002"},{"key":"bibr84-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1224116"},{"key":"bibr85-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-59349-9_18"},{"key":"bibr86-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2007.0120"},{"key":"bibr87-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4665"},{"key":"bibr88-2042018811419889","first-page":"421","volume":"11","author":"Portella G.","year":"1999","journal-title":"Oncol Res"},{"key":"bibr89-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-0128"},{"key":"bibr90-2042018811419889","doi-asserted-by":"crossref","unstructured":"Ravaud, A., De La Fouchardiere, C., Asselineau, J., Delord, J.P., Do Cao, C., Niccoli, P. et al. (2010) Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.\n                      Oncologist\n                      15: 212\u2013213; author reply 214.","DOI":"10.1634\/theoncologist.2009-0303"},{"key":"bibr91-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1655"},{"key":"bibr92-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01119"},{"key":"bibr93-2042018811419889","first-page":"6105","volume":"61","author":"Ringel M.D.","year":"2001","journal-title":"Cancer Res"},{"key":"bibr94-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2461"},{"key":"bibr95-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8170"},{"key":"bibr96-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2378"},{"key":"bibr97-2042018811419889","first-page":"1821","volume":"12","author":"Santoro M.","year":"1996","journal-title":"Oncogene"},{"key":"bibr98-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02289"},{"key":"bibr99-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra013339"},{"key":"bibr100-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.7815"},{"key":"bibr101-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-1228"},{"key":"bibr102-2042018811419889","doi-asserted-by":"crossref","unstructured":"Schwartz, G., Robertson, S., Shen, A., Wang, E., Pace, L., Dials, H.\n                      et al\n                      . (2009) A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors.\n                      J Clin Oncol\n                      Suppl 27(15S): abstract 3513.","DOI":"10.1200\/jco.2009.27.15_suppl.3513"},{"key":"bibr103-2042018811419889","doi-asserted-by":"crossref","unstructured":"Sherman, E., Fury, M., Tuttle, R., Ghossein, R., Stambuk, H., Baum, M.\n                      et al\n                      . (2009) Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma.\n                      J Clin Oncol\n                      Suppl 27(15S): abstract 6059.","DOI":"10.1200\/jco.2009.27.15_suppl.6059"},{"key":"bibr104-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa075853"},{"key":"bibr105-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E"},{"key":"bibr106-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.04.016"},{"key":"bibr107-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0937"},{"key":"bibr108-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2010.03.013"},{"key":"bibr109-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-004-1018-0"},{"key":"bibr110-2042018811419889","first-page":"3741","volume":"82","author":"Soh E.Y.","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"bibr111-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(96)80038-9"},{"key":"bibr112-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.986"},{"key":"bibr113-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1097\/00125480-200111000-00005"},{"key":"bibr114-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1002\/path.1511"},{"key":"bibr115-2042018811419889","unstructured":"Tuttle, R., Ball, D., Byrd, D., Dilawari, R., Doherty, G., Duh, Q.Y.\n                      et al\n                      . (2011) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): thyroid carcinoma. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf."},{"key":"bibr116-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.4.8388"},{"key":"bibr117-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021186"},{"key":"bibr118-2042018811419889","first-page":"2449","volume":"84","author":"Venkataraman G.M.","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"bibr119-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4561"},{"key":"bibr120-2042018811419889","first-page":"1207","volume":"11","author":"Viglietto G.","year":"1995","journal-title":"Oncogene"},{"key":"bibr121-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0292"},{"key":"bibr122-2042018811419889","first-page":"4645","volume":"62","author":"Wedge S.R.","year":"2002","journal-title":"Cancer Res"},{"key":"bibr123-2042018811419889","doi-asserted-by":"crossref","unstructured":"Wells, S., Robinson, B., Gagel, R., Dralle, H., Fagin, J., Santoro, M.\n                      et al\n                      . (2010) Vandetanib (Van) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA).\n                      J Clin Oncol\n                      28(15S): abstract 5503.","DOI":"10.1200\/jco.2010.28.15_suppl.5503"},{"key":"bibr124-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6604"},{"key":"bibr125-2042018811419889","first-page":"405","volume":"70","author":"Williams S.D.","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"bibr126-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1631"},{"key":"bibr127-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.0978"},{"key":"bibr128-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0007"},{"key":"bibr129-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0927"},{"key":"bibr130-2042018811419889","first-page":"2316","volume":"63","author":"Xing M.","year":"2003","journal-title":"Cancer Res"},{"key":"bibr131-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1994.4.427"},{"key":"bibr132-2042018811419889","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2812"}],"container-title":["Therapeutic Advances in Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2042018811419889","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2042018811419889","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2042018811419889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:33:34Z","timestamp":1777592014000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2042018811419889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,26]]},"references-count":132,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1177\/2042018811419889"],"URL":"https:\/\/doi.org\/10.1177\/2042018811419889","relation":{},"ISSN":["2042-0188","2042-0196"],"issn-type":[{"value":"2042-0188","type":"print"},{"value":"2042-0196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,26]]}}}